This approval
covers Wave 2 of PATH. A full revision is necessary for the
collection of Wave 3 data. Before submitting the information
collection request for Wave 3 to OMB, NIDA/FDA should report to OMB
regarding: a) the response rates associated with the full baseline
wave, including screening, interview completion, and bio-specimen
response; b) Wave 2 retention, recruitment rates for the “age in to
adult” and “age in of shadow” subsamples; c) the results of
nonresponse analysis and statistical approach for addressing
non-response, as well as implications for the study going forward;
and d) the statistical approach to be applied to the bio-specimen
data to address potential non-response bias from lower consent and
cooperation rates with this aspect of the study. Per prior terms of
clearance, NIDA and FDA will create a public use dataset from each
wave’s data, making it available to the public on-line within 18
months of completion of each wave. Data underlying
government-funded scientific publications will be made available to
the public, consistent with NIH guidelines for implementing OSTP’s
Public Access to the Results of Federally Funded Research. This
study is not specifically designed to provide nationally
representative estimates of prevalence. As such, FDA and NIDA will
always present such cross-sectional prevalence estimates in
conjunction with estimates from HHS’ signature nationally
representative studies such as CPS-TUPS, NHIS, NATS, and
NSDUH.
Inventory as of this Action
Requested
Previously Approved
09/30/2016
36 Months From Approved
11/30/2015
193,243
0
546,222
56,939
0
132,620
0
0
0
This is a revision request (OMB
0925-0664, expires 11/30/2015) for the Population Assessment of
Tobacco and Health (PATH) Study to conduct the second wave of data
collection. The PATH Study is a national longitudinal cohort study
on tobacco use behavior, attitudes, and health among the U.S.
household population of adults age 18 and older and youth ages 12
to 17. The PATH Study conducts annual interviews and collects
biospecimens from adults to measure and report within-person
changes and between-person differences in tobacco product use
behaviors, attitudes, and health effects within the cohort over
time. Data from the PATH Study will enhance the knowledge base that
informs FDA's regulatory decisions and actions under the 2009
Family Smoking Prevention and Tobacco Control Act (TCA). The TCA
authorized FDA to regulate tobacco products, including
tobacco-product advertising, labeling, marketing, constituents,
ingredients, and additives.
US Code:
42
USC 285o Name of Law: Public Health Service Act
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.